BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 31836811)

  • 1. Mebendazole augments sensitivity to sorafenib by targeting MAPK and BCL-2 signalling in n-nitrosodiethylamine-induced murine hepatocellular carcinoma.
    Younis NS; Ghanim AMH; Saber S
    Sci Rep; 2019 Dec; 9(1):19095. PubMed ID: 31836811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Telmisartan attenuates N-nitrosodiethylamine-induced hepatocellular carcinoma in mice by modulating the NF-κB-TAK1-ERK1/2 axis in the context of PPARγ agonistic activity.
    Saber S; Khodir AE; Soliman WE; Salama MM; Abdo WS; Elsaeed B; Nader K; Abdelnasser A; Megahed N; Basuony M; Shawky A; Mahmoud M; Medhat R; Eldin AS
    Naunyn Schmiedebergs Arch Pharmacol; 2019 Dec; 392(12):1591-1604. PubMed ID: 31367864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perindopril, fosinopril and losartan inhibited the progression of diethylnitrosamine-induced hepatocellular carcinoma in mice via the inactivation of nuclear transcription factor kappa-B.
    Saber S; Mahmoud AAA; Goda R; Helal NS; El-Ahwany E; Abdelghany RH
    Toxicol Lett; 2018 Oct; 295():32-40. PubMed ID: 29859236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The potential chemotherapeutic effect of β-ionone and/or sorafenib against hepatocellular carcinoma via its antioxidant effect, PPAR-γ, FOXO-1, Ki-67, Bax, and Bcl-2 signaling pathways.
    Abd-Elbaset M; Mansour AM; Ahmed OM; Abo-Youssef AM
    Naunyn Schmiedebergs Arch Pharmacol; 2020 Sep; 393(9):1611-1624. PubMed ID: 32270258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of doxorubicin-induced autophagy in hepatocellular carcinoma Hep3B cells by sorafenib--the role of extracellular signal-regulated kinase counteraction.
    Manov I; Pollak Y; Broneshter R; Iancu TC
    FEBS J; 2011 Sep; 278(18):3494-507. PubMed ID: 21790999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of VX2 as a Hepatocellular Carcinoma Model: Comparison of the Molecular Reaction of VX2 and HepG2 Tumor Cells to Sorafenib In Vitro.
    Nass N; Streit S; Wybranski C; Jürgens J; Brauner J; Schulz N; Powerski M; Ricke J; Kalinski T; Dudeck O; Seidensticker M
    Anticancer Res; 2017 Jan; 37(1):87-93. PubMed ID: 28011478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. COX-2/PGE2 Axis Regulates HIF2α Activity to Promote Hepatocellular Carcinoma Hypoxic Response and Reduce the Sensitivity of Sorafenib Treatment.
    Dong XF; Liu TQ; Zhi XT; Zou J; Zhong JT; Li T; Mo XL; Zhou W; Guo WW; Liu X; Chen YY; Li MY; Zhong XG; Han YM; Wang ZH; Dong ZR
    Clin Cancer Res; 2018 Jul; 24(13):3204-3216. PubMed ID: 29514844
    [No Abstract]   [Full Text] [Related]  

  • 8. Silencing
    Zhu Q; Ren H; Li X; Qian B; Fan S; Hu F; Xu L; Zhai B
    Aging (Albany NY); 2020 Nov; 12(22):22975-23003. PubMed ID: 33203790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 2-Methoxyestradiol synergizes with sorafenib to suppress hepatocellular carcinoma by simultaneously dysregulating hypoxia-inducible factor-1 and -2.
    Ma L; Li G; Zhu H; Dong X; Zhao D; Jiang X; Li J; Qiao H; Ni S; Sun X
    Cancer Lett; 2014 Dec; 355(1):96-105. PubMed ID: 25218350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic inhibition of HCC and liver cancer stem cell proliferation by targeting RAS/RAF/MAPK and WNT/β-catenin pathways.
    Galuppo R; Maynard E; Shah M; Daily MF; Chen C; Spear BT; Gedaly R
    Anticancer Res; 2014 Apr; 34(4):1709-13. PubMed ID: 24692700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemopreventive and antitumor effects of benzyl isothiocynate on HCC models: A possible role of HGF /pAkt/ STAT3 axis and VEGF.
    Zakaria S; Helmy MW; Salahuddin A; Omran G
    Biomed Pharmacother; 2018 Dec; 108():65-75. PubMed ID: 30216802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sodium orthovanadate overcomes sorafenib resistance of hepatocellular carcinoma cells by inhibiting Na
    Jiang W; Li G; Li W; Wang P; Xiu P; Jiang X; Liu B; Sun X; Jiang H
    Sci Rep; 2018 Jun; 8(1):9706. PubMed ID: 29946188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sorafenib-mediated targeting of the AAA⁺ ATPase p97/VCP leads to disruption of the secretory pathway, endoplasmic reticulum stress, and hepatocellular cancer cell death.
    Yi P; Higa A; Taouji S; Bexiga MG; Marza E; Arma D; Castain C; Le Bail B; Simpson JC; Rosenbaum J; Balabaud C; Bioulac-Sage P; Blanc JF; Chevet E
    Mol Cancer Ther; 2012 Dec; 11(12):2610-20. PubMed ID: 23041544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NF-kappaB inhibition in human hepatocellular carcinoma and its potential as adjunct to sorafenib based therapy.
    Wu JM; Sheng H; Saxena R; Skill NJ; Bhat-Nakshatri P; Yu M; Nakshatri H; Maluccio MA
    Cancer Lett; 2009 Jun; 278(2):145-155. PubMed ID: 19303700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Possible role of selective, irreversible, proteasome inhibitor (carfilzomib) in the treatment of rat hepatocellular carcinoma.
    Mansour MA; Aljoufi MA; Al-Hosaini K; Al-Rikabi AC; Nagi MN
    Chem Biol Interact; 2014 May; 215():17-24. PubMed ID: 24632418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autocrine vascular endothelial growth factor signaling promotes cell proliferation and modulates sorafenib treatment efficacy in hepatocellular carcinoma.
    Peng S; Wang Y; Peng H; Chen D; Shen S; Peng B; Chen M; Lencioni R; Kuang M
    Hepatology; 2014 Oct; 60(4):1264-77. PubMed ID: 24849467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways.
    Gedaly R; Angulo P; Hundley J; Daily MF; Chen C; Koch A; Evers BM
    Anticancer Res; 2010 Dec; 30(12):4951-8. PubMed ID: 21187475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel complementary antitumour effects of celastrol and metformin by targeting IκBκB, apoptosis and NLRP3 inflammasome activation in diethylnitrosamine-induced murine hepatocarcinogenesis.
    Saber S; Ghanim AMH; El-Ahwany E; El-Kader EMA
    Cancer Chemother Pharmacol; 2020 Feb; 85(2):331-343. PubMed ID: 31989218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TRAIL-induced apoptosis of hepatocellular carcinoma cells is augmented by targeted therapies.
    Koehler BC; Urbanik T; Vick B; Boger RJ; Heeger S; Galle PR; Schuchmann M; Schulze-Bergkamen H
    World J Gastroenterol; 2009 Dec; 15(47):5924-35. PubMed ID: 20014456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Macrolide antibiotics differentially influence human HepG2 cytotoxicity and modulate intrinsic/extrinsic apoptotic pathways in rat hepatocellular carcinoma model.
    Abdel-Hamid NI; El-Azab MF; Moustafa YM
    Naunyn Schmiedebergs Arch Pharmacol; 2017 Apr; 390(4):379-395. PubMed ID: 28070612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.